Summary
We have studied the contribution of beta1- and beta2-adrenoceptors to the isoprenaline-induced changes in heart rate, blood pressure, forearm blood flow, peripheral vascular resistance, and finger tremor. This was achieved by a comparison of the effects of atenolol 50 mg, ICI 118551 25 mg, propranolol 80 mg, atenolol 50 mg combined with ICI 118551 25 mg, propranolol 80 mg combined with ICI 118551 25 mg, and placebo.
Atenolol 50 mg and ICI 118551 25 mg caused similar attenuations in the isoprenaline-induced changes in heart rate and diastolic blood pressure, but the responses after the combination of atenolol and ICI 118551 were similar to those after propranolol 80 mg.
There was no difference in the forearm blood flow responses to isoprenaline after atenolol 50 mg and ICI 118551, but atenolol 50 mg did not reduce peripheral vascular resistance compared with placebo. Both responses after treatment with atenolol combined with ICI 118551 were similar to those after propranolol 80 mg.
Finger tremor responses to isoprenaline were antagonized by ICI 118551 alone and in combination with propranolol and atenolol but not by atenolol alone, suggesting that the response is beta2-adrenoceptor-mediated.
We conclude that the cardiovascular responses to isoprenaline are mediated by both beta1- and beta2-adrenoceptors, whereas the finger tremor response is mediated by beta2-adrenoceptors.
Similar content being viewed by others
References
Brick I, Hutchison KJ, McDevitt DG, Roddie IC, Shanks RG (1968) Comparison of the effects of ICI 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol 34: 127–149
Arnold JMO, McDevitt DG (1983) Heart rate and blood pressure responses to intravenous boluses of isoprenaline in the presence of propranolol, practolol and atropine. Br J Clin Pharmacol 16: 175–184
Mougeot G, Hugues FC, Julien D, Marche J (1981) Influence of propranolol and acebutolol on isoprenaline-induced changes in heart rate and peripheral blood flow in man. Arch Int Pharmacodyn Ther 251: 116–125
Arnold JMO, McDevitt DG (1983) Enhancement of physiological finger tremor by intravenous isoprenaline infusions in man: evaluation of its role in the assessment of β-adrenoceptor antagonists. Br J Clin Pharmacol 18: 145–152
Arnold JMO, O'Connor PC, Riddell JG, Harron DWG, Shanks RG, McDevitt DG (1985) Effects of the β-adrenoceptor antagonist ICI 118551 on exercise tachycardia and isoprenaline-induced β-adrenoceptor responses in man. Br J Clin Pharmacol 19: 619–630
Riddell JG, Shanks RG (1985) Effects of betaxolol, propranolol and atenolol on isoproterenol-induced beta-adrenoceptor responses. Clin Pharmacol Ther 38: 554–559
Ellis ME, Sahay JN, Chatterjee SS, Cruikshank JM, Ellis SH (1981) Cardioselectivity of atenolol in asthmatic patients. Eur J Clin Pharmacol 21: 173–176
Bilski AJ, Halliday SE, Fitzgerald JD, Wale JL (1983) The pharmacology of a β2-selective adrenoceptor antagonist (ICI 118551). J Cardiovasc Pharmacol 5: 430–437
Greenfield ADM (1960) Venous occlusion plethysmography. Meth Med Res 8: 293–301
Conover WJ (1980) Practical non-parametric statistics, 2nd edn. Wiley and Sons, New York, p 299
Epstein SE, Robinson BF, Kahler RL, Braunwald E (1965) Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J Clin Invest 44: 1745–1753
Stiles CL, Taylor S, Lefkowitz RJ (1983) Human cardiac beta-adrenergic receptors: Subtype heterogeneity delineated by direct radioligand binding. Life Sci 33: 467–473
Harry JD, Norris SC, Percival PG, Young J (1984) Effects of ICI 118551 (a β2-adrenoceptor antagonist) on some cardiovascular actions of dobutamine. Br J Clin Pharmacol 17: 187–188P
McDevitt DG (1977) The assessment of beta-adrenoceptor blocking drugs in man. Br J Clin Pharmacol 4: 413–425
Shand DG (1976) Pharmacokinetics of propranolol: A review. Postgrad Med J 52 [Suppl 4]: 22–25
Finch MB, O'Connor PC, Harron DWG, Shanks RG (1983) Comparison of the effects of pindolol and propranolol on heart rate after acute and chronic administration. Br J Clin Pharmacol 15: 431–434
Pringle TH, McNeill AJ, Riddell JG, Shanks RG (1987) The assessment of the β-adrenoceptor blocking activity and cardioselectivity of Koe 3290 in normal subjects. Br J Clin Pharmacol 24: 581–589
McCaffery PM, Riddell JG, Shanks RG (1988) The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118551. J Cardiovasc Pharmacol 11: 543–551
Marsden CD, Meadows JC, Langle GW, Watson RS (1969) The role of the ballistocardiac impulse in the genesis of tremor. Brain 92: 647–662
Arnold JMO, McDevitt DG (1983) An assessment of physiological finger tremor as an indicator of β-adrenoceptor function. Br J Clin Pharmacol 16: 167–174
Arnold JMO, McDevitt DG (1986) Reflex vagal withdrawal and the hemodynamic response to intravenous isoproterenol in the presence of beta-antagonists. Clin Pharmacol Ther 40: 199–208
Imai Y, Satoh K, Taira N (1978) Role of the peripheral vasculature in changes in venous return caused by isoproterenol, norepinephrine, and methoxamine in anesthetized dogs. Circ Res 48: 553–561
Strauss MH, Reeves RA, Smith DL, Leenen FHH (1986) The role of cardiac beta1-receptors in the hemodynamic response to a beta2-agonist. Clin Pharmacol Ther 40: 108–115
Fitzgerald DE, Harry JD (1985) Experience with a Doppler technique to investigate the interaction of isoprenaline and various β-adrenoceptor blocking drugs on blood vessels in the lower limb. Eur J Clin Pharmacol 29: 447–454
Shepherd JT (1983) Circulation to skeletal muscle. In: Shepherd JT, Abboud FM, Geiger SR (eds). Handbook of physiology (sect 2). The cardiovascular system, vol III. Peripheral circulation and organ blood flow. Am Physiol Soc Bethesda, Maryland, part I, pp 319–370
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pringle, T.H., Riddell, J.G. & Shanks, R.G. Characterization of the beta-adrenoreceptors which mediate the isoprenaline-induced changes in finger tremor and cardiovascular function in man. Eur J Clin Pharmacol 35, 507–514 (1988). https://doi.org/10.1007/BF00558246
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558246